CancerMaster™ – A Clinically Validated Integrated NGS Solution for Precision Oncology
The Role of NGS Panels in Precision Oncology
In the era of precision medicine, an NGS panel is no longer just a genetic testing tool. It is critical infrastructure for clinical decision-making. CancerMaster™ is a hybrid capture–based targeted NGS panel covering 524 cancer-related genes, designed as an integrated platform that combines sequencing, automated analysis, and reporting in a single streamlined workflow. Developed in collaboration with Severance Hospital (Yonsei Cancer Center), CancerMaster™ has completed both analytical and clinical validation using real-world patient data. The results were published in Scientific Reports.
Comprehensive Biomarker Analysis in a Single Workflow
One of the key strengths of CancerMaster™ is its ability to evaluate multi-layered biomarkers within a single platform.
The panel simultaneously analyzes:
- SNVs / Indels
- CNVs
- Gene Fusions
- EBV / HPV infection status
- Microsatellite Instability (MSI)
- Tumor Mutational Burden (TMB)
- HLA typing
By integrating these biomarkers into a unified workflow, CancerMaster™ improves clinical efficiency compared with conventional panels that often require multiple separate assays.
Analytical Performance Validated by Reference Materials
Its analytical performance has been objectively validated. Using standardized reference materials, CancerMaster™ demonstrated 100% reproducibility, 99% analytical sensitivity, and 94% overall accuracy, with an average on-target sequencing depth of approximately 1,200×. This deep coverage supports reliable detection of low-frequency variants and ensures robust performance across diverse tumor samples.
Benchmarking Against the Global Standard Panel TSO500
Importantly, CancerMaster™ was directly benchmarked against the globally adopted Illumina TruSight Oncology 500 (TSO500). In a head-to-head comparison of 23 tumor samples, the two panels showed high concordance across most variant types. Notably, CancerMaster™ uniquely identified an ERBB2 missense mutation that was not reported by TSO500. These findings indicate that CancerMaster™ achieves performance comparable to a global standard panel, while demonstrating potential differentiation in clinically meaningful variant detection.
Clinical Validation Using Real-world Patient Data
Clinical validation was conducted in a cohort of 668 real-world patients at Severance Hospital. Across multiple solid tumor types, including gastric and colorectal cancers, CancerMaster™ consistently detected key therapeutic target mutations such as TP53, KRAS, and PIK3CA. In gastric cancer, ERBB2 amplification was identified in 11.7% of cases, MSI-H in 8.5%, and TMB-H in 5.1%. A strong correlation between MSI and TMB was observed in the overall cohort (r=0.75, p<10⁻¹⁵), with even higher concordance in colorectal cancer (r=0.87). MSI detection accuracy reached 95.2%, and EBV detection accuracy was 96.4%. These results were obtained under tumor-only conditions in a real clinical setting, underscoring the practical applicability of the platform.
Automated Bioinformatics Pipeline and Integrated Reporting
CancerMaster™ is not merely a gene panel; it incorporates an automated asynchronous and parallel bioinformatics pipeline. Analytical modules are processed in parallel, and results are automatically generated in two formats: a research-level detailed variant report and a clinically actionable report. This structure improves laboratory workflow efficiency and significantly reduces overall turnaround time (TAT). Designed specifically for tumor-only analysis, CancerMaster™ employs optimized germline filtering strategies and a CNV baseline normalization framework to support real-world clinical laboratory environments.
Conclusion: A Clinically Validated Solution for Precision Oncology
CancerMaster™ is a solution that integrates four key strengths: analytical performance, clinical validation, automation, and cost competitiveness. In direct comparisons with globally established panels, it demonstrated analytical performance that is fully comparable, while also showing additional clinical value in certain areas. Supported by performance validated with real-world clinical data and a cost-effective structure, CancerMaster™ provides an integrated NGS solution that can be applied across clinical laboratories, contract research organizations (CROs), research institutions, and pharmaceutical and biotechnology settings involved in precision oncology analysis.
Related Publication (Scientific Reports)
The analytical and clinical validation results of CancerMaster™ have been published in Scientific Reports. 👉 https://www.nature.com/articles/s41598-026-37991-0
CancerMaster™ combines deep sequencing performance, multi-biomarker analysis, and clinically validated results into a single integrated NGS platform. By enabling comprehensive genomic profiling within a streamlined workflow, it supports clinical laboratories and research institutions in advancing precision oncology.
Learn more about the CancerMaster™ panel and explore how it supports comprehensive precision oncology analysis.
👉 https://www.celemics.com/products/ready-to-use-ngs-panel/somatic-cancer/cancermaster/
#PrecisionOncology #CancerGenomics #NGSPanel #TargetCapture
#ClinicalNGS #CancerBiomarkers #TumorProfiling #GenomicMedicine
#ScientificReports